top of page

Investors

Kadimastem on Tel-Aviv Stock Exchange

For More Investors Info.

Thanks! Message sent.

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

June 23, 2024 at 7:08:03 AM

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

February 28, 2024 at 2:10:37 PM

Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq

February 14, 2024 at 10:00:00 PM

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

February 7, 2024 at 10:44:02 AM

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

January 24, 2024 at 10:00:00 PM

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

January 22, 2024 at 8:10:35 AM

Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes

November 7, 2023 at 7:16:58 AM

Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx

June 20, 2023 at 7:32:57 AM

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

May 15, 2023 at 11:10:42 AM

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

May 9, 2023 at 6:16:05 AM

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

March 19, 2023 at 7:43:32 AM

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

February 19, 2023 at 10:13:44 AM

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

February 15, 2023 at 10:16:24 AM

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

February 5, 2023 at 8:15:19 AM

Kadimastem Announces it raised appx 7.5 million NIS by rights offering

January 9, 2023 at 2:19:09 PM

Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant

December 20, 2022 at 9:55:35 AM

Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes

September 28, 2022 at 6:47:50 AM

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

August 9, 2022 at 7:36:45 AM

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement

June 8, 2022 at 6:24:04 AM

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

May 30, 2022 at 12:56:40 PM

Kadimastem Expands R&D Program to Include Multiple Sclerosis

May 17, 2022 at 9:00:00 PM

Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority

March 3, 2022 at 1:08:29 PM

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

December 13, 2021 at 10:36:37 AM

ILEX Medical to Invest 10 million NIS ($3.2 million)

November 29, 2021 at 12:20:17 PM

We rang the TASE bell today!

November 15, 2021 at 6:28:17 AM

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

October 26, 2021 at 5:52:59 AM

Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

October 12, 2021 at 1:45:54 PM

Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan

July 21, 2021 at 12:46:30 PM

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article

May 11, 2021 at 11:30:15 AM

Kadimastem Raises NIS 22.3 Million ($6.8 Million)

April 26, 2021 at 7:19:04 AM

Kadimastem Granted a Patent in Israel for the Treatment of ALS

March 9, 2021 at 9:00:16 AM

Kadimastem Announces Executive Management Changes

January 31, 2021 at 10:59:20 AM

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

December 15, 2020 at 1:56:27 PM

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

August 3, 2020 at 7:11:53 AM

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:25:35 PM

Kadimastem Announces the Completion of Treatment for Cohort B

July 27, 2020 at 1:25:54 PM

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

July 27, 2020 at 1:27:08 PM

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

July 27, 2020 at 1:28:11 PM

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

November 17, 2019 at 2:10:12 PM

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:30:03 PM

Kadimastem Announces Leadership Changes

May 20, 2019 at 1:09:25 PM

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

April 18, 2019 at 1:45:49 PM

Appointment of a new CFO for Kadimastem

March 3, 2019 at 7:44:59 AM

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

February 24, 2019 at 7:48:37 AM

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

February 17, 2019 at 8:00:17 AM

Kadimastem to be included in the TASE Indices

November 27, 2018 at 10:46:59 AM

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

November 14, 2018 at 2:48:21 PM

Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes

November 12, 2018 at 2:48:44 PM

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

November 4, 2018 at 2:47:51 PM

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

October 9, 2018 at 9:47:57 AM

bottom of page